OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting

On September 23, 2026 OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, reported that topline results from the Combi-TED Phase 2 international clinical trial of Tedopi in metastatic Non-Small Cell Lung Cancer sponsored by FoRT have been selected for an oral presentation at the 2026 Annual Meeting of the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) in Madrid, Spain (October 23-27, 2026).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Federico Cappuzzo, MD, PhD, Director of Medical Oncology at the National Cancer Institute Regina Elena (Rome, Italy) and Lead Investigator of the trial, will present topline results from the Combi-TED trial evaluating Tedopi in second-line treatment in combination with anti-PD1 or chemotherapy in patients with metastatic Non-Small Cell Lung Cancer (NSCLC).

"Results of a multicenter, phase II, open-label, randomized trial evaluating OSE2101 plus docetaxel or OSE2101 plus nivolumab as second-line therapy in metastatic non-small-cell lung cancer (NSCLC) progressing after first-line chemo-immunotherapy"

Rapid Oral Presentation
Session: Non-Small Cell Lung Cancer, Metastatic
Abstract 2661RO
Room: Barcelona Auditorium, Hall 9
October 25, 2026, 8:30-10:00am CET
Combi-TED is an open label, randomized, three-arm Phase 2 study evaluating Tedopi in combination with the anti-PD1 immune checkpoint inhibitor Opdivo (nivolumab), with docetaxel or docetaxel alone (reference arm) as second-line treatment in 105 HLA-A2 positive patients with metastatic NSCLC and no evidence of EGFR mutations or ALK or ROS1 rearrangement, after first-line chemo-immunotherapy. The primary endpoint is 1-year survival rate. The trial is conducted in 23 sites in France, Italy and Spain.
(NCT04884282).

(Press release, OSE Immunotherapeutics, SEP 23, 2026, View Source [SID1234671012])